Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma

Laurence Albiges, Mohamed Salem, Brian Rini, Bernard Escudier

    Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

    46 Citations (Scopus)

    Résumé

    Vascular endothelial growth factor (VEGF) is, to date, the key element in the pathogenesis of renal cell carcinoma (RCC). VEGF pathway activation is responsible for the recruitment, migration, and expansion of endothelial cells, with this angiogenesis tumor model being characteristic of RCC. Different strategies have been developed for almost a decade to block the VEGF pathway in this setting. Four different compounds were approved for metastatic RCC (mRCC) in the past 6 years: bevacizumab, sunitinib, sorafenib, and pazopanib. Axitinib and tivozanib are also promising compounds under evaluation. The revolution in the management and prognosis of patients with mRCC is ongoing.

    langue originaleAnglais
    Pages (de - à)813-833
    Nombre de pages21
    journalHematology/Oncology Clinics of North America
    Volume25
    Numéro de publication4
    Les DOIs
    étatPublié - 1 août 2011

    Contient cette citation